Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 19/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | CTSH | P09668 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14975127 | 0.87 | CTSK (0.44) | CTSKCTSLCTSBCTSH | |
| SCHEMBL4820415 | 0.78 | CTSK (0.60) | CTSKCTSLCTSBCTSH | |
| SCHEMBL4820406 | 0.78 | CTSK (0.60) | CTSKCTSLCTSBCTSH | |
| SCHEMBL25333528 | 0.77 | CTSK (0.40) | CTSKCTSLCTSBCTSH | |
| SCHEMBL25333530 | 0.77 | CTSK (0.40) | CTSKCTSLCTSBCTSH | |
| SCHEMBL9994206 | 0.76 | CTSK (0.38) | CTSK | |
| SCHEMBL14542293 | 0.75 | CTSK (0.38) | CTSKCTSLCTSBCTSH | |
| SCHEMBL3496194 | 0.75 | FOLH1 (0.41) | CTSKCTSLCTSBCTSH | |
| SCHEMBL19744852 | 0.75 | CTSK (0.38) | CTSKCTSLCTSBCTSH | |
| SCHEMBL328961 | 0.74 | CTSK (0.50) | CTSKCTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885ACACB 367/4885ACACA 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.